Retatrutide (CAS NO: 2381089-83-2 ), a cutting-edge triple hormone receptor agonist innovated by Eli Lilly, stands out in the field of metabolic disease treatment due to its unique mechanism of action. It simultaneously activates three key receptors: glucose-dependent otropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR), forming a multi-target regulatory network that brings comprehensive therapeutic benefits. Here is a detailed elaboration on its product functions:
• Precise Blood Glucose Regulation
The activation of GLP-1R by retatrutide triggers a series of glucose-lowering effects: it stimulates pancreatic β-cells to secrete in a glucose-dependent manner, ensuring effective release when blood glucose rises while avoiding hypoglycemia risks; it also inhibits the secretion of glucagon, a hormone that elevates blood glucose, thereby reducing excessive glucose production in the liver. Additionally, GLP-1R activation slows down gastric emptying, extending the digestion and absorption time of food, which not only helps stabilize postprandial blood glucose but also reduces hunger sensations, indirectly contributing to calorie control. On the other hand, GIPR activation enhances the otropic effect, amplifying the secretion response to glucose stimulation, and participates in lipid metabolism regulation by promoting the breakdown of triglycerides and reducing lipid accumulation in peripheral tissues. This dual-receptor synergy enables retatrutide to achieve more stable and comprehensive blood glucose control compared to single-receptor agonists.
• Powerful Weight Loss Efficacy
The activation of GCGR by retatrutide plays a pivotal role in weight management. It promotes the decomposition of white adipose tissue, converting stored fat into free fatty acids for energy supply; at the same time, it boosts basal metabolic rate, increasing the body's daily energy consumption even at rest. Clinical trials have fully verified its remarkable weight loss potential. In a Phase II clinical study involving obese patients without diabetes, the 24-week data showed significant differences between the retatrutide groups and the placebo group: the 1mg group achieved a weight reduction of 7.2%, the 4mg combined group (adjusted dosage regimen) reached 12.9%, the 8mg combined group dropped by 17.3%, and the 12mg group decreased by 17.5%, while the placebo group only saw a 1.6% reduction. As the treatment period extended to 48 weeks, the weight loss effect became more pronounced: the 1mg group lost 8.7% of body weight, the 4mg combined group 17.1%, the 8mg combined group 22.8%, and the 12mg group an impressive 24.2%, in stark contrast to the 2.1% reduction in the placebo group. These data fully demonstrate that retatrutide can achieve sustained and dose-dependent weight loss, making it a promising option for obesity management.
• Comprehensive Metabolic Health Improvement
Retatrutide constructs a dynamic balance system for energy metabolism through the coordinated action of the three receptors, covering the entire process of energy "intake-storage-consumption": GLP-1R inhibits hunger signals in the hypothalamus, with clinical data showing a 51% reduction in hunger sensations, effectively curbing excessive food intake; GIPR enhances muscle glycogen synthesis, ensuring that the body preferentially utilizes fat for energy while preserving lean body mass—studies indicate that lean body mass loss is only 0.9% during treatment, avoiding the muscle wasting problem common in traditional weight loss methods; GCGR activates thermogenesis in adipose tissue, with a 90% increase in UCP1 (a key protein regulating fat burning), significantly enhancing fat oxidation efficiency. Beyond energy regulation, retatrutide also reverses 47% of liver fat deposition, reducing the risk of non-alcoholic fatty liver disease; improves cardiac function, with an 8.5% increase in left ventricular ejection fraction (LVEF), enhancing cardiac pumping efficiency; and preserves muscle mass, which is crucial for maintaining basal metabolism and physical function. These effects collectively contribute to the overall improvement of metabolic health, breaking the vicious cycle of obesity and metabolic disorders.
• Potential Extensive Therapeutic Prospects
Preclinical studies have revealed broader application potential of retatrutide beyond metabolic diseases. In animal models, it exhibits significant antidepressant and anxiolytic activities, possibly by regulating neurotransmitter systems related to mood, such as the serotonin and dopamine pathways, making it a potential candidate for treating depression and anxiety disorders. Moreover, its neuroprotective properties have been observed: it can reduce oxidative stress and inflammatory responses in the brain, protect neurons from damage, and may play a role in preventing or slowing the progression of neurodegenerative diseases like Alzheimer's and Parkinson's. Additionally, animal studies have shown that retatrutide improves learning and memory abilities, possibly by enhancing synaptic plasticity in the hippocampus, suggesting its potential in promoting human cognitive function—though further clinical trials are needed to confirm these effects.
Retatrutide is primarily indicated for the treatment of obesity and type 2 diabetes. For obesity, it is suitable for adult patients with a body mass index (BMI) ≥30 kg/m² (meeting the diagnostic criteria for obesity) or BMI ≥27 kg/m² accompanied by obesity-related comorbidities such as hypertension, dyslipidemia, or non-alcoholic fatty liver disease, helping them achieve sustainable weight loss and reduce associated health risks. For type 2 diabetes, it serves as an adjunctive therapy to diet and exercise, particularly beneficial for patients with poor blood glucose control despite conventional treatments or those with concurrent obesity, as it can simultaneously address both hyperglycemia and excess weight, improving overall disease prognosis.
With its multi-target mechanism, significant clinical effects, and broad application prospects, retatrutide represents a major breakthrough in the field of metabolic disease treatment, offering new hope for patients with obesity, type 2 diabetes, and related metabolic disorders.
Our company is a modern advanced enterprise specializing in production and exportation of APIs, Pharmaceutical intermediates, plant extracts etc. Our products are widely used in medicine, health care products, cosmetics, nutritional supplements and food additives areas. Our factory covers an area of 95 acres, the proposed construction of the plant will be GMP standards, the factory environment clean and tidy, rational layout, with large and medium-sized production workshop and repocessed shop. It is equipped with advanced equipment quality inspection and research center. Those products of both quality and technical content have reached the domestic advanced level. Since its establishment, the company has attached great importance to the team training and technical reform. Our modern production equipment guarantees for a fast and effective production with a superior degree of accuracy throughout the whole production line, everything is done in-house, processing, extraction, packaging and transportation of all links, ensuring maximum quality and efficiency. We are constantly research and development new ingredients and innovative new products, have earned the respect & Admiration from the worldwide customers. After years of continuous development, company has been accumulated rich experience in international trade and customer resources, established a stable customer base and perfect marketing service network. In addition, the company has established long-term technical cooperation with experts and professors from many universities and research institutes in the province.
Our Advantages.
1.High quality with competitive price.
2. All purity>99%.
3. We are manufacturer and can provide high quality products with factory price.
4. Reliable delivery: Timely and efficient transportation to ensure that your production schedule is met.
Fast and safe delivery.
1. Parcel can be sent out in 24 hours after payment tracking number available.
2. Secure and discreet shipment verious transportation methods for your choice.
3. Customs pass rate >99%.
We have clients throughout the world.
1. Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their different desire.
2. Market feedback and goods feedback will be appreciated, meeting customers’ requirement is our principal responsibility.
3. High quality, competitive price, fast delivery, first-class service gain the trust and praise from all the customers.
United States
United Kingdom
Poland
Austria
Palestine
